Compare ARK Genomic Revolution ETF (ARKG) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs T Rowe Price Group Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while T Rowe Price Group Inc trades at $118.55 (market cap $25.40B). The key difference: T Rowe Price Group Inc pays a 4.39% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | TROW | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $120.16 |
52-Week Low | $23.09 | $86.19 |
Market Cap | — | $25.40B |
Enterprise Value | — | $22.11B |
Dividend Yield | — | 4.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
T. Rowe Price (TROW) trades at $118.55, up 1.28% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 28.28% net income margin and a P/E of 12.72, indicating potential undervaluation. Recent earnings have mostly beaten expectations, and the company maintains robust cash flow, supporting a sustainable dividend. Strategic enhancements to its institutional business and positive media coverage highlight ongoing growth initiatives.
The outlook for TROW is positive, driven by solid fundamentals and strategic positioning, though investor caution is warranted given the majority hold rating from analysts and competitive pressures in asset management. Upside potential exists if the company continues to exceed earnings estimates and manage equity outflows effectively, but macroeconomic volatility remains a key risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
